Camp4 Therapeutics Corp (CAMP)

$3.03 -0.06 (-2.10%)
Market Cap 71.07M
Revenue (ttm) 294.95M
Net Income (ttm) -32.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.02%
Debt to Equity Ratio 0.00
Volume 17,019
Avg Vol 31,734
Day's Range N/A - N/A
Shares Out 20.16M
Stochastic %K 0%
Beta N/A
Analysts Strong Sell
Price Target $19.00

Latest News on CAMP

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 4:05 PM EDT - 7 days ago

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Mar 18, 2025, 8:00 AM EDT - 17 days ago

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 13, 2025, 10:39 PM EDT - 21 days ago

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 13, 2025, 2:58 PM EDT - 22 days ago

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

CAMP4 to Participate in Upcoming Investor Conferences

Feb 6, 2025, 8:00 AM EST - 2 months ago

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

Jan 7, 2025, 4:05 PM EST - 3 months ago

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 4 months ago

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

CAMP4 Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 4:05 PM EST - 4 months ago

CAMP4 Reports Third Quarter 2024 Financial Results

CAMP4 Analyst Highlights Rare Disease Platform Potential

Nov 5, 2024, 3:06 PM EST - 5 months ago

CAMP4 Analyst Highlights Rare Disease Platform Potential

CAMP4 Announces Pricing of Initial Public Offering

Oct 10, 2024, 7:07 PM EDT - 6 months ago

CAMP4 Announces Pricing of Initial Public Offering

Camp4 Therapeutics Targets IPO On Early Positive Results

Oct 1, 2024, 4:30 PM EDT - 6 months ago

Camp4 Therapeutics Targets IPO On Early Positive Results

Genetic disease biotech CAMP4 Therapeutics files for a $75 million IPO

Sep 20, 2024, 3:35 PM EDT - 7 months ago

Genetic disease biotech CAMP4 Therapeutics files for a $75 million IPO

Kaiser Permanente-backed biopharma CAMP4 files for US IPO

Sep 20, 2024, 2:23 PM EDT - 7 months ago

Kaiser Permanente-backed biopharma CAMP4 files for US IPO

CAMP4 Therapeutics IPO Registration Document (S-1)

Sep 20, 2024, 1:35 PM EDT - 7 months ago

CAMP4 Therapeutics IPO Registration Document (S-1)

CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

Sep 17, 2024, 8:00 AM EDT - 7 months ago

CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders